{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:25:00Z","timestamp":1777483500102,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,8]]},"abstract":"<jats:p>Alcohol-associated hepatitis (AH) is a critical condition with high mortality rates and is worsened by infections. Organ failure is strongly associated with intestinal dysbiosis. Emerging research suggests that gut microbiota modulation with probiotics can improve AH outcomes. This study investigated the clinical and microbiome effects of high-dose probiotic infusion (HDPI) compared with corticosteroid therapy (CST) and fecal microbiota transplantation (FMT) in severe AH. Patients with biopsy-proven severe-AH were enrolled from March 2019 to June 2020 and matched for age and disease severity. The patients received HDPI (n\u2005=\u200520), FMT (n\u2005=\u200516), or CST (n\u2005=\u200514). HDPI consists of a potent probiotic mix delivered via a nasoduodenal tube for 6 days. The primary outcome was survival at 90-days. Stool samples were subjected to 16S and 18S rRNA sequencing to assess significant bacterial and fungal taxa and their interactions at baseline and post treatment. At 90-days, survival rates were 55%, 64.3%, and 87.5% (HDPI, CST, respectively). HDPI did not beneficially impact bacterial alpha-diversity but significantly altered beta-diversity. Notably, the number of pathogenic bacteria, such as <jats:italic toggle=\"yes\">Bilophila<\/jats:italic> and <jats:italic toggle=\"yes\">Roseburia<\/jats:italic> increased. Fungal analysis revealed no significant changes in alpha diversity, but significant dissimilarities in beta diversity post-HDPI. New fungal genera such as Basidiomycota and Phragmoplastophyta have emerged, with significant deleterious expansion in fungal communities and damaging modifications between fungal\u2013bacterial interactions. HDPI failed to outperform CST in improving the clinical outcomes of patients with severe AH. While HDPI influenced both bacterial and fungal microbiomes, it also led to the persistence of pathogenic communities. FMT showed superior survival outcomes, highlighting the urgent need for further controlled trials.<\/jats:p>","DOI":"10.1097\/md.0000000000040429","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T20:02:38Z","timestamp":1731355358000},"page":"e40429","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Clinical outcomes and associated bacterial and fungal microbiota changes after high dose probiotic therapy for severe alcohol-associated hepatitis: An observational study"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-336X","authenticated-orcid":false,"given":"Cyriac Abby","family":"Philips","sequence":"first","affiliation":[{"name":"Clinical and Translational Hepatology, The Liver Institute, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"},{"name":"Department of Clinical Research, Division of Gut Microbiome and the Liver, The Liver Institute, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Ahamed","sequence":"additional","affiliation":[{"name":"Gastroenterology and Advanced GI Endoscopy, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharun Tom","family":"Oommen","sequence":"additional","affiliation":[{"name":"Gastroenterology and Advanced GI Endoscopy, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nibin","family":"Nahaz","sequence":"additional","affiliation":[{"name":"Gastroenterology and Advanced GI Endoscopy, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Tharakan","sequence":"additional","affiliation":[{"name":"Gastroenterology and Advanced GI Endoscopy, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasidharan","family":"Rajesh","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Gastroenterology and Hepatology, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Augustine","sequence":"additional","affiliation":[{"name":"Gastroenterology and Advanced GI Endoscopy, Center of Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"101123","DOI":"10.1016\/j.aohep.2023.101123","article-title":"Gut dysbiosis in alcoholic liver disease: wonderful dilemma?","volume":"28","author":"Abenavoli","year":"2023","journal-title":"Ann Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/jgh.16199","article-title":"Alcohol, the gut microbiome, and liver disease.","volume":"38","author":"Jew","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1258062","DOI":"10.3389\/fphar.2023.1258062","article-title":"Gut microbiota in alcohol-related liver disease: pathophysiology and gut-brain cross talk.","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.2147\/IJGM.S420195","article-title":"Roles of gut microbiota in alcoholic liver disease.","volume":"16","author":"Zhang","year":"2023","journal-title":"Int J Gen Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MOG.0000000000001013","article-title":"The role of the microbiome in liver disease.","volume":"40","author":"Sch\u00f6ler","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"R6-20250504","first-page":"381","article-title":"Update on the role of the gut microbiota on alcohol-associated liver disease.","volume":"17","author":"Schnabl","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12664-021-01157-9","article-title":"The role of gut microbiota in clinical complications, disease severity, and treatment response in severe alcoholic hepatitis.","volume":"41","author":"Philips","year":"2022","journal-title":"Indian J Gastroenterol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/gutjnl-2016-313170","article-title":"Fungal dysbiosis in cirrhosis.","volume":"67","author":"Bajaj","year":"2018","journal-title":"Gut"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1984122","DOI":"10.1080\/19490976.2021.1984122","article-title":"Gut non-bacterial microbiota contributing to alcohol-associated liver disease.","volume":"13","author":"Gao","year":"2021","journal-title":"Gut Microbes"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jhep.2022.12.006","article-title":"Fungal infections and the fungal microbiome in hepatobiliary disorders.","volume":"78","author":"Hartmann","year":"2023","journal-title":"J Hepatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis.","volume":"37","author":"Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care.","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"goac074","DOI":"10.1093\/gastro\/goac074","article-title":"Clinical outcomes, and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala.","volume":"10","author":"Philips","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial.","volume":"17","author":"Pande","year":"2023","journal-title":"Hepatol Int"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1054265","DOI":"10.3389\/fnut.2022.1054265","article-title":"Microbial treatment of alcoholic liver disease: a systematic review and meta-analysis.","volume":"9","author":"Wang","year":"2022","journal-title":"Front Nutr"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1358063","DOI":"10.3389\/fcimb.2024.1358063","article-title":"Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis.","volume":"14","author":"Xiong","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1002\/cpbi.100","article-title":"QIIME 2 enables comprehensive end-to-end analysis of diverse microbiome data and comparative studies with publicly available data.","volume":"70","author":"Estaki","year":"2020","journal-title":"Curr Protoc Bioinformatics"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1002\/cpz1.254","article-title":"Automation of QIIME2 metagenomic analysis platform.","volume":"1","author":"Fung","year":"2021","journal-title":"Curr Protoc"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.gendis.2019.12.005","article-title":"Microbiome data analysis with applications to pre-clinical studies using QIIME2: Statistical considerations.","volume":"8","author":"Rai","year":"2019","journal-title":"Genes Dis"},{"key":"R20-20250504","article-title":"Bioinformatics training and education program by the National Cancer Institute Center for Cancer Research."},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"943609","DOI":"10.3389\/fcimb.2022.943609","article-title":"Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects.","volume":"12","author":"Morales","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.12688\/f1000research.9050.1","article-title":"CoNet app: inference of biological association networks using Cytoscape.","volume":"5","author":"Faust","year":"2016","journal-title":"F1000Res"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e01294","DOI":"10.1128\/mBio.01294-18","article-title":"Drivers of microbiome biodiversity: a review of general rules, feces, and ignorance.","volume":"9","author":"Reese","year":"2018","journal-title":"mBio"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fmicb.2015.00713","article-title":"The reduced genomes of Parcubacteria (OD1) contain signatures of a symbiotic lifestyle.","volume":"6","author":"Nelson","year":"2015","journal-title":"Front Microbiol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e236235","DOI":"10.1136\/bcr-2020-236235","article-title":"Brevundimonas diminuta coinfection as source of pyogenic liver abscess.","volume":"14","author":"Burch","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/cells9010176","article-title":"Diet, gut microbiota and non-alcoholic fatty liver disease: three parts of the same axis.","volume":"9","author":"Quesada-V\u00e1zquez","year":"2020","journal-title":"Cells"},{"key":"R28-20250504","article-title":"Tissierella praeacuta bacteremia secondary to fecal exposure.","volume":"112","author":"Welsh","year":"2015","journal-title":"Case reports"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/microorganisms10122427","article-title":"The Weissella genus: clinically treatable bacteria with antimicrobial\/probiotic effects on inflammation and cancer.","volume":"10","author":"Ahmed","year":"2022","journal-title":"Microorganisms"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.diagmicrobio.2010.04.005","article-title":"Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection.","volume":"70","author":"Chen","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3114\/sim.2008.61.14","article-title":"Environmental isolation of black yeast-like fungi involved in human infection.","volume":"61","author":"Vicente","year":"2008","journal-title":"Stud Mycol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"e1618","DOI":"10.1016\/S2214-109X(21)00350-8","article-title":"A global call for talaromycosis to be recognised as a neglected tropical disease.","volume":"9","author":"Narayanasamy","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5009\/gnl18579","article-title":"The role of intestinal fungi and its metabolites in chronic liver diseases.","volume":"14","author":"You","year":"2020","journal-title":"Gut Liver"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:01:04Z","timestamp":1746320464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":32,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040429","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}